Financial Performance - The company's operating revenue for 2024 was ¥489,929,618.41, a decrease of 2.87% compared to ¥504,419,868.40 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥49,582,532.45, reflecting a decline of 21.35% from ¥63,045,312.79 in 2023[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥44,484,267.74, down 24.33% from ¥58,786,096.02 in 2023[20]. - The total assets at the end of 2024 were ¥790,269,703.56, a decrease of 5.79% from ¥838,823,832.71 at the end of 2023[20]. - The net assets attributable to shareholders at the end of 2024 were ¥744,848,639.94, down 6.79% from ¥799,105,245.54 at the end of 2023[20]. - The basic earnings per share for 2024 was ¥0.3443, a decrease of 20.70% from ¥0.5629 in 2023[20]. - Total revenue for 2024 was approximately ¥489.93 million, a decrease of 2.87% compared to ¥504.42 million in 2023[88]. - Functional feed additives accounted for 60.93% of total revenue, with a year-on-year increase of 6.77%[88]. - Domestic revenue decreased by 14.65% to approximately ¥303.40 million, while overseas revenue increased by 25.24% to approximately ¥186.53 million[88]. Dividend Distribution - The company plans to distribute a cash dividend of 3.2 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[3]. - The total number of hours for outsourced labor was 62,057.46, with total payments amounting to 1,859,043.75 yuan[185]. - The company has a total distributable profit of 166,676,374.26 yuan, with cash dividends accounting for 100% of the profit distribution[188]. - The company will not issue bonus shares and will not increase capital from the capital reserve for the 2024 profit distribution plan[188]. - The company’s profit distribution plan was approved by the board and will be submitted to the shareholders' meeting for final approval[188]. - The company’s net profit for 2024 is projected to be 49,582,532.45 yuan, with a parent company net profit of 45,617,068.63 yuan[188]. Operational Overview - The company has a total registered capital of 151 million RMB, with its headquarters located in Shanghai[16]. - The company operates several wholly-owned subsidiaries, including Chengdu Meiyide Biotechnology Co., Ltd. and Suzhou Meino Biotechnology Co., Ltd.[14]. - The company’s registered address has changed multiple times since its establishment in 1997, with the current address being No. 151, Lihong Road, Jiading District, Shanghai[16]. - The company’s official website is www.sinomenon.com, providing further information and updates[16]. - The company has established a comprehensive supplier selection and management mechanism, implementing a standardized procurement process based on production plans and market conditions[62]. - The production model is primarily "sales-driven," with monthly production plans formulated based on sales forecasts and inventory levels, ensuring safety stock for high-demand products[63]. Research and Development - The company has strengthened its R&D capabilities, achieving 2 new invention patents and 16 utility model patents in 2024, along with publishing 4 scientific papers[68]. - The company collaborates with several universities to enhance its research and development capabilities, focusing on core technologies such as formulation and biological enzymatic technology[68]. - The company continues to invest heavily in R&D, resulting in new product launches and technological innovations that contribute to new growth points[84]. - The company is focusing on the development and market investment of nutritional feed additives and flavoring agents for ruminants, aiming to enhance market share and influence in the dairy cow sector[130]. Market Expansion - The company has a comprehensive sales network covering over 40 countries and regions, expanding its international market presence[44]. - The company is expanding its product development through synthetic biology technology to enhance enzymatic processing of various non-grain plant protein sources[57]. - The company is focusing on expanding its international market presence, aiming for sustained double-digit growth[79]. - The company plans to enter the European market by Q2 2024, targeting a revenue contribution of $100 million in the first year[9]. - The company is actively pursuing innovation through product upgrade projects and the introduction of new technologies and products[78]. Environmental Compliance - The company has obtained a pollutant discharge permit valid until December 20, 2028, with no changes during the reporting period[197]. - The company has implemented various pollution control technologies, including dry/wet dust removal and biological treatment processes, to ensure compliance with emission standards[198]. - The company has established an environmental self-monitoring plan and has conducted monitoring that meets the required standards[199]. - The company has developed an emergency response plan for environmental incidents, enhancing its ability to respond to pollution events[200]. Corporate Governance - The company has established a market value management system and disclosed a valuation enhancement plan[139]. - The company emphasizes strict compliance with information disclosure regulations, ensuring timely and accurate communication with investors[145]. - The company has maintained independence from its controlling shareholder, ensuring no interference in decision-making[142]. - The company has a robust investor relations management system, ensuring the protection of minority investors' rights[146]. - The company held a total of 4 shareholder meetings during the reporting period, ensuring all shareholders had the opportunity to exercise their rights[141]. Employee Management - As of December 31, 2024, the company has 406 employees, with over 44% holding a bachelor's degree or higher, and a 17.81% year-on-year increase in employees with a master's degree or higher[77]. - The company strictly adheres to labor laws and provides various insurance and benefits for employees, including medical, pension, unemployment, work injury, maternity insurance, and housing fund[182]. - The company emphasizes talent development and has established a comprehensive training system to enhance the effectiveness of training programs[183].
美农生物(301156) - 2024 Q4 - 年度财报